Literature DB >> 23921949

Heterogeneity of response to biologic treatment: perspective for psoriasis.

Emily Edson-Heredia1, Kimberly L Sterling2, Carlos I Alatorre2, Gebra Cuyun Carter2, Rosirene Paczkowski2, Victoria Zarotsky3, Tomoko Maeda-Chubachi2.   

Abstract

Psoriasis treatment responses are affected by patient characteristics. However, the literature does not contain reviews of factors that affect the response to biologic therapies. We therefore performed a comprehensive literature search to identify papers describing demographic, lifestyle, and clinical factors associated with response to biologic drug therapy in psoriatic patients. We found that age, gender, ethnicity, alcohol consumption, smoking, geographic location, age at diagnosis, duration and severity of psoriasis, and baseline C-reactive protein levels did not consistently affect response to biologic psoriasis therapy. However, increased body mass index (BMI) appears to adversely affect responses. It might therefore be valuable to include BMI as a stratification variable in future studies of psoriasis therapies and to consider a patient's weight or BMI when selecting a systemic psoriasis treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23921949     DOI: 10.1038/jid.2013.326

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  32 in total

Review 1.  Review of treatment response in rheumatoid arthritis: assessment of heterogeneity.

Authors:  Iris Goetz; Gebra Cuyún Carter; Melanie Lucero; Victoria Zarotsky; Carlos I Alatorre; Ronald A Cantrell; Rosirene Paczkowski; Kimberly L Sterling
Journal:  Curr Med Res Opin       Date:  2011-01-27       Impact factor: 2.580

Review 2.  Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment.

Authors:  Sheldon Greenfield; Richard Kravitz; Naihua Duan; Sherrie H Kaplan
Journal:  Am J Med       Date:  2007-04       Impact factor: 4.965

3.  Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages.

Authors:  Richard L Kravitz; Naihua Duan; Joel Braslow
Journal:  Milbank Q       Date:  2004       Impact factor: 4.911

4.  Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.

Authors:  Mark Lebwohl; Newman Yeilding; Philippe Szapary; Yuhua Wang; Shu Li; Yaowei Zhu; Kristian Reich; Richard G Langley; Kim A Papp
Journal:  J Am Acad Dermatol       Date:  2010-10       Impact factor: 11.527

Review 5.  A comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areas.

Authors:  C I Alatorre; G C Carter; C Chen; C Villarivera; V Zarotsky; R A Cantrell; I Goetz; R Paczkowski; D Buesching
Journal:  Int J Clin Pract       Date:  2011-07-01       Impact factor: 2.503

6.  Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.

Authors:  Alan Menter; Kenneth B Gordon; Craig L Leonardi; Yihua Gu; Orin M Goldblum
Journal:  J Am Acad Dermatol       Date:  2010-06-03       Impact factor: 11.527

7.  Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.

Authors:  R J B Driessen; J B Boezeman; P C M van de Kerkhof; E M G J de Jong
Journal:  Br J Dermatol       Date:  2008-01-28       Impact factor: 9.302

8.  Low-dose etanercept therapy in moderate to severe psoriasis in Korean.

Authors:  Jung Im Na; Jun Hyung Kim; Kyoung Chan Park; Sang Woong Youn
Journal:  J Dermatol       Date:  2008-08       Impact factor: 4.005

9.  Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

Authors:  Alan Menter; Neil J Korman; Craig A Elmets; Steven R Feldman; Joel M Gelfand; Kenneth B Gordon; Alice B Gottlieb; John Y M Koo; Mark Lebwohl; Henry W Lim; Abby S Van Voorhees; Karl R Beutner; Reva Bhushan
Journal:  J Am Acad Dermatol       Date:  2009-06-03       Impact factor: 11.527

10.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Authors:  Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

View more
  14 in total

Review 1.  The role of the gut microbiome in systemic inflammatory disease.

Authors:  Jose C Clemente; Julia Manasson; Jose U Scher
Journal:  BMJ       Date:  2018-01-08

2.  Psychosocial aspects of obesity in adults with psoriasis: A systematic review.

Authors:  N T Pavlova; K Kioskli; C Smith; F Picariello; L Rayner; R Moss-Morris
Journal:  Skin Health Dis       Date:  2021-05-03

3.  Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Authors:  Richard B Warren; Catherine H Smith; Zenas Z N Yiu; Darren M Ashcroft; Jonathan N W N Barker; A David Burden; Mark Lunt; Kathleen McElhone; Anthony D Ormerod; Caroline M Owen; Nick J Reynolds; Christopher E M Griffiths
Journal:  J Invest Dermatol       Date:  2015-06-08       Impact factor: 8.551

Review 4.  Diet and psoriasis, part I: Impact of weight loss interventions.

Authors:  Maya Debbaneh; Jillian W Millsop; Bhavnit K Bhatia; John Koo; Wilson Liao
Journal:  J Am Acad Dermatol       Date:  2014-04-04       Impact factor: 11.527

5.  Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility.

Authors:  Xianyong Yin; Hui Qi Low; Ling Wang; Yonghong Li; Eva Ellinghaus; Jiali Han; Xavier Estivill; Liangdan Sun; Xianbo Zuo; Changbing Shen; Caihong Zhu; Anping Zhang; Fabio Sanchez; Leonid Padyukov; Joseph J Catanese; Gerald G Krueger; Kristina Callis Duffin; Sören Mucha; Michael Weichenthal; Stephan Weidinger; Wolfgang Lieb; Jia Nee Foo; Yi Li; Karseng Sim; Herty Liany; Ishak Irwan; Yikying Teo; Colin T S Theng; Rashmi Gupta; Anne Bowcock; Philip L De Jager; Abrar A Qureshi; Paul I W de Bakker; Mark Seielstad; Wilson Liao; Mona Ståhle; Andre Franke; Xuejun Zhang; Jianjun Liu
Journal:  Nat Commun       Date:  2015-04-23       Impact factor: 14.919

6.  Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study.

Authors:  R B Warren; A Marsden; B Tomenson; K J Mason; M M Soliman; A D Burden; N J Reynolds; D Stocken; R Emsley; C E M Griffiths; C Smith
Journal:  Br J Dermatol       Date:  2018-08-28       Impact factor: 9.302

7.  Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.

Authors:  A B Gottlieb; J-P Lacour; N Korman; S Wilhelm; Y Dutronc; A Schacht; J Erickson; L Zhang; L Mallbris; S Gerdes
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-11-02       Impact factor: 6.166

8.  Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series.

Authors:  Michelle Phung; Jorge R Georgakopoulos; Arvin Ighani; Lyne Giroux; Jensen Yeung
Journal:  JAAD Case Rep       Date:  2018-03-31

Review 9.  The influence of body weight of patients with chronic plaque psoriasis on biological treatment response.

Authors:  Anna Kisielnicka; Aneta Szczerkowska-Dobosz; Roman J Nowicki
Journal:  Postepy Dermatol Alergol       Date:  2020-05-05       Impact factor: 1.837

10.  Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab.

Authors:  Katherine Houghton; Dhaval Patil; Braulio Gomez; Steven R Feldman
Journal:  Dermatol Ther (Heidelb)       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.